JARDIANCE® (Empagliflozin)
The content on this website is in relation to adult patients
Dose & Administration
JARDIANCE® (empagliflozin) is simple to initiate at 10 mg dosing across all indications
Quick links
Once daily, any time of day
Swallow whole with water, with or without food
No upper age limit**
Indications
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
Indications
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, type 1 diabetes, and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy
** Volume depletion: Osmotic diuresis may lead to a modest decrease in blood pressure. Use with caution in patients for whom a drop in blood pressure could pose a risk e.g. patients aged 75 or older.
Straightforward dose adjustment with JARDIANCE®1
Dose adjustment recommendations based on eGFR (mL/min/1.73m2)
In patients tolerating empagliflozin 10 mg once daily who have an eGFR ≥60 mL/min/1.73 m2 and need tighter glycaemic control, the dose can be increased to 25 mg once daily.
The glucose lowering efficacy of empagliflozin is reduced in patients with an eGFR <45 mL/min/1.73 m2 and likely absent in patients with an eGFR <30 mL/min/1.73 m2. Therefore, if eGFR falls below 45 mL/min/1.73 m2, additional glucose lowering treatment should be considered.
Learn more
Digital patient booklet
Which patients may be suitable for empagliflozin treatment?
JARDIANCE Initiation & Management guide for T2D, CHF and CKD
Abbreviations
CHF: chronic heart failure; CKD: chronic kidney failure; CrCL: creatinine clearance; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; T2D: type 2 diabetes mellitus.
References
- JARDIANCE® (empagliflozin) Summary of Product Characteristics (SmPC). Available at: http://www.medicines.org.uk/emc/medicine/28973.
PC-GB-109669
March 2024